Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) – Investment analysts at HC Wainwright reduced their FY2028 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a note issued to investors on Thursday, January 23rd. HC Wainwright analyst J. Pantginis now expects that the biopharmaceutical company will post earnings of $0.16 per share for the year, down from their previous forecast of $6.05. HC Wainwright has a “Buy” rating and a $16.00 price target on the stock. The consensus estimate for Esperion Therapeutics’ current full-year earnings is ($0.28) per share.
Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) last released its quarterly earnings data on Thursday, November 7th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.01). The firm had revenue of $51.63 million during the quarter, compared to analyst estimates of $55.44 million. During the same period in the prior year, the company posted ($0.37) earnings per share.
Get Our Latest Analysis on ESPR
Esperion Therapeutics Stock Performance
Esperion Therapeutics stock opened at $1.99 on Monday. Esperion Therapeutics has a fifty-two week low of $1.58 and a fifty-two week high of $3.94. The company has a market capitalization of $392.11 million, a P/E ratio of -3.11 and a beta of 1.03. The stock has a 50-day simple moving average of $2.46 and a 200-day simple moving average of $2.17.
Institutional Inflows and Outflows
Large investors have recently made changes to their positions in the business. Traphagen Investment Advisors LLC purchased a new position in shares of Esperion Therapeutics in the 3rd quarter worth $27,000. Xponance Inc. purchased a new position in shares of Esperion Therapeutics in the 2nd quarter worth $28,000. Versor Investments LP purchased a new position in shares of Esperion Therapeutics in the 3rd quarter worth $44,000. American Century Companies Inc. purchased a new position in shares of Esperion Therapeutics in the 2nd quarter worth $50,000. Finally, SJS Investment Consulting Inc. purchased a new position in shares of Esperion Therapeutics in the 4th quarter worth $55,000. Hedge funds and other institutional investors own 47.39% of the company’s stock.
About Esperion Therapeutics
Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.
Further Reading
- Five stocks we like better than Esperion Therapeutics
- The Role Economic Reports Play in a Successful Investment Strategy
- Sizing Up a New Opportunity for NVIDIA Investors
- 3 Tickers Leading a Meme Stock Revival
- Is DeepSeek Challenging NVIDIA’s AI Dominance?
- Election Stocks: How Elections Affect the Stock Market
- The 3 Biggest M&A Stock Opportunities for 2025
Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.